Radionuclide therapies have been applied in the diverse fields of medicine, and it has been demonstrated the usefulness of it, especially in the field of oncology. Accurate dosimetric assessment is imperative during radionuclide therapy, in order to optimize the treatment efficacy for target sites and to minimize the radiation exposure for normal organ. Recent advancement in imaging technology permits the precise determination of the absorbed dose non-invasively. This imaging based dosimetry can be routinely applicable to the bedside in the near future.
Treatment Outcome

Although the modern medicine has progressed for a long time, there are empirical studies shows the effectiveness of traditional and complementary treatments (TCT) in curing chronic diseases. In Malaysia, TCT is often related to the use of herbs and meditation that vary according to ethnicity. Each ethnic group has its own beliefs system in curing diseases. This study mainly aims to provide an overview on the perceptions of the effectiveness TCT in curing chronic diseases. The authors used electronic database to select 10 journal articles according to inclusion and exclusion criteria. Findings show the highest statistic among Sabah natives and followed by Malay ethnic on believing in the effectiveness of TCT. Price and encouragement from family and friends are the main influencing factors of taking TCT. We suggest that counsellors need to be aware of the TCT practices on particular culture in order to increase respect and trust in the helping relationships.
Traditional Treatment

Objective. This is a cross-sectional study aimed to determine the time intervals from the first symptom to surgery of 37 patients with ovarian malignancies who underwent surgery at a tertiary government hospital from June to October 2019.

Methods. Structured interviews of patients and chart reviews were conducted to identify the intervals and the reasons behind such. The data were analyzed using Stata/SE 14.1, with the time intervals presented as medians and the reasons as frequencies. Multinomial logistic regression analysis established the association of time intervals with the extent of surgery and final stage of ovarian malignancies.

Results. The median Total Time Interval from the first symptom to surgery was 214 days. The longest delay was the Total System Interval (from the first visit at the tertiary hospital to surgery) with a median of 70 days. This was followed closely by Patient Interval (from the first symptom to consult with the initial physician) with a median of 64 days. A distant third was the Initial Physician Interval (from the consult with the initial physician to the first visit at the tertiary hospital) with a median of 29 days. Most common reasons for the delays were the patients not acknowledging the gravity of their condition for the Patient Interval; choice to go to other hospitals, distance and laboratory works or diagnostics for the Initial Physician Interval; waiting for laboratory work-ups for the First System Interval; and waiting for other departments' clearance for the Second System Interval. The most common first symptom was abdominal enlargement. The length of interval and the final stage (p=0.056 for Stage III and p=0.162 for Stage IV)) as well as extent of surgery (p=0.093) did not show significant association.

Conclusion. The time interval from first symptom to surgery showed a median of 214 days. The greatest delay is contributed by Total System Interval followed by Patient Interval due to varying reasons. Length of time intervals, however, was not found to be significantly associated with the extent of surgery and final stage

OBJECTIVE: This study described childhood interstitial lung disease profiles at the Philippine Children‘s Medical Center (2013-2022). MATERIALS AND METHODS: A retrospective chart review at PCMC analyzed pediatric interstitial lung disease cases (Jan 2013-Dec 2022). Included were patients aged 0-18 with childhood interstitial lung disease. Excluded were those with specific conditions. Data included clinical course, tests, therapeutic management, and short-term outcomes based on a previous study. RESULTS: Twenty-three patients were included in this study. Most (52.17%) were diagnosed between 2013-2017, and were within the ages of 0-2 years. Majority of patients had normal nutritional status (52.17%). Common clinical presentation on admission included breathing difficulties, with chest retractions, crackles, and hypoxemia. Few had a family history of chronic lung disease. Comorbidities included pulmonary hypertension (30.43%) and pulmonary tuberculosis (21.74%). Chest radiography revealed infiltrates in all cases, and HRCT scans showed ground glass opacities in 82.61%. Prednisone was the primary treatment (86.96%). Lung biopsy results (43.48%) were mostly unclassified or nondiagnostic, with lymphoid interstitial pneumonia as the predominant diagnosis (20%). Improvement of signs and symptoms was seen in 39.13% of cases, whereas death occurred in 21.74%. Furthermore, the outcome remained undetermined in as much as 34.78% of cases due to inadequate follow-up. CONCLUSION This retrospective study emphasizes chILD's prevalence in infants under 2 years, with male predominance. Nutritional variations underscore the need for supplementation. Various common signs include crackles, retractions, and hypoxemia, with breathing difficulty as a frequent symptom. The diagnostic process involves imaging and ancillary tests, advocating a systematic approach with noninvasive methods like CXR and HRCT, reserving lung biopsy for inconclusive cases. Corticosteroids, whether used alone or in combination, prove beneficial in managing chILD by suppressing inflammation.
Treatment Outcome

No abstract available.
Emergencies* ; Emergency Treatment*

No abstract available.
Leiomyoma* ; Treatment Outcome*

No abstract available.
Retreatment* ; Treatment Failure*

No abstract available.
Adult* ; Humans ; Treatment Outcome*

Child ; Humans ; Treatment Outcome

The side effects of cerivastatin on the skeletal muscle include muscle pain, muscle weakness accompanying with the increased creatinin - kinase rarely malignant hypermyoglobin uric leading the secondary renal failure. The Bayer pharmaceutical Company withdrawed all dosage form of cerivastatin in England and America in the 8th and 9th August 2001.
Pyridines ; Withholding Treatment